Fig. 5
UTX−/− ECs-Exos promotes macrophage polarization and neurological recovery after SCI. A Immunofluorescence analysis of the level expression of CD206+ (M2)/iNOS+ (M1) (red) in F4/80+ macrophages (green) in the Sham, Vehicle, UTXf/f-Exos, and UTX−/−-Exos groups at 7 days after SCI. Scale bar, 20 μm. B Statistical analysis of mean fluorescence intensity of CD206 and iNOS in A. C Representative scatter plots of macrophage phenotypes in sham, Vehicle, UTXf/f-Exos, and UTX−/−-Exos groups at 7 days after SCI. Cells were immunolabeled with antibody-fluorophore-coupled antibodies for CD206 and CD11c. M1 macrophages are defined as CD11c+CD206− and M2 macrophages are defined as CD11c−CD206+. The numbers in the gates refer to the percentage of positive cells for each marker. D The percentage of M1 macrophages (CD11c+CD206−) and M2 macrophages (CD11c−CD206+) cells in C. E, F Distribution of the BMS scores and subscores per group at Pre-sur, 1, 3, 7, 10, 14, 21, and 28 days post-SCI. n = 8/per group. G Representative electrophysiological traces in each group at 28 days post-SCI. H, I Quantification of MEP amplitude and latent period in G. nsP > 0.05, *P < 0.05, **P < 0.01 vs. corresponding control mice. n = 5/per group